SEM-CORTICO.Severe erythema multiform: A randomized controlled trial com-paring a short systemic corticosteroids regimen to placebo in the acute established phase.
This study, called SEM-CORTICO, is for patients in hospital with a severe skin condition called erythema multiforme (EM). Researchers want to find out if a short course of steroid tablets, such as prednisolone, helps patients recover more quickly than a dummy treatment (placebo). They will compare how long it takes for patients to manage their pain, start eating solid food again, and whether they need extra emergency treatment. The study is in its final phase (Phase III), meaning it's a key step in checking if the treatment is effective and safe. The aim is to improve care for people with this challenging condition.
At a glance
What is this study about?
This research study, called SEM-CORTICO, is designed for people who have a severe skin condition called erythema multiforme (EM) and are being treated in hospital. Erythema multiforme causes painful rashes and sores, especially on the skin and sometimes in the mouth. The main goal of this study is to see if giving a short course of steroid medication, like prednisolone, can help people recover faster and feel better sooner compared to those who receive a dummy treatment (placebo).
When we talk about 'getting better faster,' we're particularly interested in a few key things. Firstly, how quickly can patients get their pain under control so it's mild enough (a score of less than 4 out of 10) and they don't need strong pain relief for 48 hours? Secondly, can they start eating chopped or solid food again? And thirdly, do they avoid needing additional emergency steroid treatment? By looking at these factors, the researchers hope to understand if this steroid treatment is a helpful way to manage severe EM.
This is a Phase III study, which means it's one of the final steps in checking if a new treatment works and is safe. The results will help doctors decide if a short course of steroids should become a standard treatment for severe erythema multiforme, potentially improving recovery and reducing discomfort for patients in the future.
Key takeaways
- The study investigates a short course of steroids for severe erythema multiforme.
- It compares steroid treatment to a dummy pill (placebo).
- Key goals are better pain control and quicker return to eating solid food.
- The study involves daily checks while in hospital and follow-up for six months.
- It aims to find better ways to treat this serious skin condition.
Who may be eligible?
This study is open to adults aged 18 years and older. There is no upper age limit, meaning people of all adult ages can take part. Both men and women are welcome to participate in this research.
To be eligible, you must have been diagnosed with a severe form of erythema multiforme and currently be receiving hospital care for your condition. The study aims to recruit a broad group of adult patients to ensure the results are widely applicable.
Specific medical details will be checked by the study team to make sure it's safe and appropriate for you to join. This helps ensure the study is conducted properly and that all participants receive suitable care.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a severe form of erythema multiforme?
- Are you currently in hospital for your condition?
- Are you willing to potentially receive either a steroid or a dummy pill?
What does participation involve?
If you decide to take part in this study, you would be given either a short course of steroid tablets (like prednisolone) or a dummy pill (placebo). The treatment would be given for a specific period during your hospital stay. You would be closely monitored by doctors and nurses every day. This includes regular checks on your pain levels, how well you're eating, and how your skin is healing. They will also look out for any new symptoms or side effects.
Your pain will be rated daily, and your ability to eat solid food will be checked. Your skin and any sores will be looked at by a doctor each day. After you leave the hospital, there will be follow-up checks at fixed times – one week, two weeks, one month, three months, and six months – to see how you're recovering and if there are any lasting effects or if your symptoms return. You will also be asked about your general well-being and quality of life at various points. The total duration of active follow-up for the study will be six months.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is erythema multiforme (EM)?
Erythema multiforme is a skin condition that causes rashes and sores, sometimes on other body parts. This study focuses on severe forms of the condition.
What is a placebo?
A placebo is a dummy treatment that looks just like the real medicine but contains no active drug. It helps researchers compare if the real medicine is truly effective.
Will I know if I'm getting the steroid or the placebo?
No, in this type of study (called 'blinded'), neither you nor your doctors will know who is getting the steroid and who is getting the placebo until the study is over. This ensures fair results.
What kind of steroids would I receive?
The study uses strong steroid tablets like prednisolone or methylprednisolone, given for a short period.
How long will I be followed after leaving the hospital?
You'll have follow-up checks for up to six months after you leave the hospital to monitor your recovery and overall health.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.